| Year |
Citation |
Score |
| 2020 |
Peake BF, Eze SM, Yang L, Castellino RC, Nahta R. Correction: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling. Oncotarget. 11: 4074-4075. PMID 33216843 DOI: 10.18632/oncotarget.27779 |
0.414 |
|
| 2020 |
Zhao J, Meisel J, Guo Y, Nahta R, Hsieh KL, Peng L, Wei Z, O'Regan R, Li X. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. Breast Cancer Research and Treatment. PMID 32715443 DOI: 10.1007/S10549-020-05819-8 |
0.466 |
|
| 2019 |
Meisel JL, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer. PMID 31806448 DOI: 10.1016/J.Clbc.2019.09.003 |
0.562 |
|
| 2018 |
O'Regan RM, Nahta R. Targeting Forkhead Box M1 Transcription Factor in Breast Cancer. Biochemical Pharmacology. PMID 29859987 DOI: 10.1016/J.Bcp.2018.05.019 |
0.618 |
|
| 2018 |
Paplomata E, Nahta R. ABP 980: Promising Trastuzumab Biosimilar for HER2-Positive Breast Cancer. Expert Opinion On Biological Therapy. PMID 29350568 DOI: 10.1080/14712598.2018.1430761 |
0.49 |
|
| 2018 |
Akamandisa MP, Nie K, Wen J, Nahta R, Hambardzumyan D, Castellino RC. Abstract B05: Mechanisms of PPM1D-mediated tumorigenesis in diffuse intrinsic pontine glioma (DIPG) Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-B05 |
0.396 |
|
| 2017 |
Peake BF, Eze SM, Yang L, Castellino RC, Nahta R. Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling. Oncotarget. 8: 94393-94406. PMID 29212236 DOI: 10.18632/Oncotarget.21765 |
0.607 |
|
| 2017 |
Qi L, Zhang B, Zhang S, Ci X, Wu Q, Ma G, Luo A, Fu L, King JL, Nahta R, Dong JT. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. Oncotarget. PMID 28415602 DOI: 10.18632/Oncotarget.16425 |
0.634 |
|
| 2016 |
Wen J, Lee J, Malhotra A, Nahta R, Arnold AR, Buss MC, Brown BD, Maier C, Kenney AM, Remke M, Ramaswamy V, Taylor MD, Castellino RC. WIP1 modulates responsiveness to Sonic Hedgehog signaling in neuronal precursor cells and medulloblastoma. Oncogene. PMID 27086929 DOI: 10.1038/Onc.2016.96 |
0.377 |
|
| 2015 |
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, ... ... Nahta R, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology. 35: S276-304. PMID 26590477 DOI: 10.1016/J.Semcancer.2015.09.007 |
0.409 |
|
| 2015 |
Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines. 3: 519-43. PMID 26350593 DOI: 10.3390/Vaccines3030519 |
0.516 |
|
| 2015 |
Goodson WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, ... ... Nahta R, et al. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis. 36: S254-96. PMID 26106142 DOI: 10.1093/Carcin/Bgv039 |
0.329 |
|
| 2015 |
Nahta R, Al-Mulla F, Al-Temaimi R, Amedei A, Andrade-Vieira R, Bay S, G Brown D, Calaf GM, Castellino RC, Cohen-Solal KA, Colacci A, Cruickshanks N, Dent P, Di Fiore R, Forte S, et al. Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis. 36: S2-S18. PMID 26106139 DOI: 10.1093/Carcin/Bgv028 |
0.441 |
|
| 2015 |
Amin AR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, Dong JT, Kucuk O, Khan GN, Huang GS, Mi S, Lee HY, Reichrath J, Honoki K, Georgakilas AG, et al. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars in Cancer Biology. PMID 25749195 DOI: 10.1016/J.Semcancer.2015.02.005 |
0.432 |
|
| 2015 |
Taliaferro-Smith L, Oberlick E, Liu T, McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E, Nagaraju GP, Havel L, Marcus A, Nahta R, O'Regan R. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget. 6: 4757-72. PMID 25749031 DOI: 10.18632/Oncotarget.3023 |
0.571 |
|
| 2015 |
Sanabria-Figueroa E, Donnelly SM, Foy KC, Buss MC, Castellino RC, Paplomata E, Taliaferro-Smith L, Kaumaya PT, Nahta R. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1. Molecular Pharmacology. 87: 150-61. PMID 25391374 DOI: 10.1124/Mol.114.095380 |
0.498 |
|
| 2015 |
Paplomata E, Nahta R, O'Regan RM. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach? Cancer. 121: 517-26. PMID 25346473 DOI: 10.1002/Cncr.29060 |
0.571 |
|
| 2014 |
Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology. 3: e956012. PMID 25941588 DOI: 10.4161/21624011.2014.956012 |
0.529 |
|
| 2014 |
Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology. 3: e956005. PMID 25941587 DOI: 10.4161/21624011.2014.956005 |
0.453 |
|
| 2014 |
Peake BF, Nahta R. Resistance to HER2-targeted therapies: a potential role for FOXM1. Breast Cancer Management. 3: 423-431. PMID 25598845 DOI: 10.2217/Bmt.14.33 |
0.632 |
|
| 2014 |
Donnelly SM, Paplomata E, Peake BM, Sanabria E, Chen Z, Nahta R. P38 MAPK contributes to resistance and invasiveness of HER2-overexpressing breast cancer Current Medicinal Chemistry. 21: 501-510. PMID 24251561 DOI: 10.2174/0929867320666131119155023 |
0.577 |
|
| 2013 |
Griner SE, Wang KJ, Joshi JP, Nahta R. Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines. Current Pharmacogenomics and Personalized Medicine. 11: 31-41. PMID 24179558 DOI: 10.2174/1875692111311010006 |
0.643 |
|
| 2013 |
Nahta R. Human epidermal growth factor receptor 2-targeted therapies in breast cancer. Expert Opinion On Biological Therapy. 13: 949-52. PMID 23565676 DOI: 10.1517/14712598.2013.789497 |
0.592 |
|
| 2013 |
Gayle SS, Castellino RC, Buss MC, Nahta R. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. Current Medicinal Chemistry. 20: 2486-99. PMID 23531216 DOI: 10.2174/0929867311320190008 |
0.658 |
|
| 2013 |
Griner SE, Joshi JP, Nahta R. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochemical Pharmacology. 85: 46-58. PMID 23085437 DOI: 10.1016/J.Bcp.2012.10.007 |
0.462 |
|
| 2013 |
Joshi JP, Chen Z, Nahta R. Abstract 889: Growth differentiation factor 15 causes increased invasiveness and EMT in HER2-overexpressing breast cancer via activation of p38 MAPK. Cancer Research. 73: 889-889. DOI: 10.1158/1538-7445.Am2013-889 |
0.622 |
|
| 2012 |
Nahta R. New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Medical Press). 4: 53-64. PMID 23869176 DOI: 10.2147/BCTT.S24976 |
0.587 |
|
| 2012 |
Nahta R. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. Isrn Oncology. 2012: 428062. PMID 23227361 DOI: 10.5402/2012/428062 |
0.596 |
|
| 2012 |
Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R, Liu JO. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. Journal of the National Cancer Institute. 104: 1576-90. PMID 23042933 DOI: 10.1093/Jnci/Djs396 |
0.611 |
|
| 2012 |
Yehl K, Joshi JP, Greene BL, Dyer RB, Nahta R, Salaita K. Catalytic deoxyribozyme-modified nanoparticles for RNAi-independent gene regulation Acs Nano. 6: 9150-9157. PMID 22966955 DOI: 10.1021/Nn3034265 |
0.336 |
|
| 2012 |
Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemotherapy Research and Practice. 2012: 648965. PMID 22830017 DOI: 10.1155/2012/648965 |
0.6 |
|
| 2012 |
Nahta R, O'Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Research and Treatment. 135: 39-48. PMID 22527112 DOI: 10.1007/S10549-012-2067-8 |
0.592 |
|
| 2012 |
Nahta R. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Current Medicinal Chemistry. 19: 1065-1075. PMID 22229414 DOI: 10.2174/092986712799320691 |
0.594 |
|
| 2012 |
Gayle SS, Arnold SL, O'Regan RM, Nahta R. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. Anti-Cancer Agents in Medicinal Chemistry. 12: 151-62. PMID 22043997 DOI: 10.2174/187152012799015002 |
0.606 |
|
| 2012 |
O'Regan RM, Gabram S, Styblo T, Rizzo M, Wood W, Srinivasiah J, Jonas W, Schnell F, Adams A, Nahta R, Zelnak A. Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer Cancer Research. 72: 2703-2703. DOI: 10.1158/1538-7445.Am2012-2703 |
0.462 |
|
| 2012 |
Gayle SS, Nahta R. Abstract A6: Sustained MAPK signaling contributes to reduced sensitivity to lapatinib Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-A6 |
0.624 |
|
| 2012 |
Nahta R, Joshi JP, Griner SE, Adams AL, Andre F. Abstract P4-07-02: Growth differentiation factor 15, a novel mediator of progression in HER2-positive breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-07-02 |
0.541 |
|
| 2011 |
Crawford A, Nahta R. Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines. Current Pharmacogenomics and Personalized Medicine. 9: 184-190. PMID 22162984 DOI: 10.2174/187569211796957584 |
0.586 |
|
| 2011 |
Joshi JP, Brown NE, Griner SE, Nahta R. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochemical Pharmacology. 82: 1090-9. PMID 21803025 DOI: 10.1016/J.Bcp.2011.07.082 |
0.562 |
|
| 2011 |
Ozbay T, Nahta R. Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines. Breast Cancer : Basic and Clinical Research. 5: 143-54. PMID 21792311 DOI: 10.4137/BCBCR.S7156 |
0.571 |
|
| 2011 |
Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, Wu Y, Price JE, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Research. 71: 4585-97. PMID 21498634 DOI: 10.1158/0008-5472.Can-11-0127 |
0.624 |
|
| 2010 |
Nahta R, O'Regan RM. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clinical Breast Cancer. 10: S72-8. PMID 21115425 DOI: 10.3816/Cbc.2010.S.015 |
0.633 |
|
| 2010 |
Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemotherapy and Pharmacology. 65: 697-706. PMID 19636556 DOI: 10.1007/S00280-009-1075-9 |
0.592 |
|
| 2009 |
Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Current Pharmacogenomics and Personalized Medicine. 7: 263-274. PMID 20300449 DOI: 10.2174/187569209790112337 |
0.584 |
|
| 2009 |
Rowe DL, Ozbay T, O'Regan RM, Nahta R. Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin. Breast Cancer : Basic and Clinical Research. 3: 61-75. PMID 19809577 |
0.552 |
|
| 2009 |
Conforti R, Moeder C, Tomasic G, Boulet T, Nahta R, Yuan L, Spielmann M, Delaloge S, Michiels S, Rimm D, Esteva F, Andre F. Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer. Cancer Research. 69: 6063. DOI: 10.1158/0008-5472.Sabcs-6063 |
0.411 |
|
| 2008 |
Rowe DL, Ozbay T, Bender LM, Nahta R. Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Molecular Cancer Therapeutics. 7: 1900-8. PMID 18645000 DOI: 10.1158/1535-7163.Mct-08-0012 |
0.656 |
|
| 2008 |
Ozbay T, Nahta R. A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Molecular Cancer Research : McR. 6: 1052-8. PMID 18515755 DOI: 10.1158/1541-7786.Mcr-07-2126 |
0.518 |
|
| 2008 |
Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Frontiers in Bioscience : a Journal and Virtual Library. 13: 3906-12. PMID 18508484 DOI: 10.2741/2978 |
0.569 |
|
| 2008 |
Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LXH, Meslin F, Spielmann M, Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer Annals of Oncology. 19: 315-320. PMID 17804473 DOI: 10.1093/Annonc/Mdm429 |
0.549 |
|
| 2008 |
Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling (Molecular Cancer Therapeutics (2007) 6, (667-674)) Molecular Cancer Therapeutics. 7. DOI: 10.1158/1535-7163.Mct-07-11-Cor3 |
0.594 |
|
| 2008 |
Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) Cancer Research. 68. DOI: 10.1158/0008-5472.Can-68-22-Cor1 |
0.555 |
|
| 2007 |
Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 26: 3637-3643. PMID 17530017 DOI: 10.1038/Sj.Onc.1210379 |
0.625 |
|
| 2007 |
Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Molecular Cancer Therapeutics. 6: 667-74. PMID 17308062 DOI: 10.1158/1535-7163.Mct-06-0423 |
0.645 |
|
| 2007 |
Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Molecular Cancer Therapeutics. 6: 227-35. PMID 17218636 DOI: 10.1158/1535-7163.Mct-05-0499 |
0.422 |
|
| 2006 |
Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Research : Bcr. 8: 215. PMID 17096862 DOI: 10.1186/Bcr1612 |
0.576 |
|
| 2006 |
Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Molecular Cancer Therapeutics. 5: 1593-601. PMID 16818519 DOI: 10.1158/1535-7163.Mct-06-0133 |
0.567 |
|
| 2006 |
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice. Oncology. 3: 269-80. PMID 16683005 DOI: 10.1038/Ncponc0509 |
0.608 |
|
| 2006 |
Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Letters. 232: 123-38. PMID 16458110 DOI: 10.1016/J.Canlet.2005.01.041 |
0.614 |
|
| 2006 |
Esteva FJ, Anderson K, Lin F, Nahta R, Mejia J, Altundag K, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy Journal of Clinical Oncology. 24: 545-545. DOI: 10.1200/Jco.2006.24.18_Suppl.545 |
0.463 |
|
| 2005 |
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research. 65: 11118-28. PMID 16322262 DOI: 10.1158/0008-5472.Can-04-3841 |
0.51 |
|
| 2004 |
Wang W, Nahta R, Huper G, Marks JR. TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. Molecular Cancer Research : McR. 2: 442-52. PMID 15328371 |
0.592 |
|
| 2004 |
Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Research. 64: 3981-6. PMID 15173011 DOI: 10.1158/0008-5472.Can-03-3900 |
0.566 |
|
| 2004 |
Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Research. 64: 2343-6. PMID 15059883 DOI: 10.1158/0008-5472.Can-03-3856 |
0.582 |
|
| 2004 |
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 100: 499-506. PMID 14745865 DOI: 10.1002/cncr.11940 |
0.322 |
|
| 2004 |
Nahta R, Esteva FJ. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemotherapy and Pharmacology. 53: 186-90. PMID 14605867 DOI: 10.1007/S00280-003-0728-3 |
0.597 |
|
| 2003 |
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5652-9. PMID 14654548 |
0.415 |
|
| 2003 |
Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5078-84. PMID 14613984 |
0.494 |
|
| 2003 |
Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Seminars in Oncology. 30: 143-9. PMID 14613035 DOI: 10.1053/J.Seminoncol.2003.08.016 |
0.609 |
|
| 2003 |
Nahta R, Trent S, Yang C, Schmidt EV. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Research. 63: 3626-31. PMID 12839951 |
0.471 |
|
| 2003 |
Nahta R, Hortobagyi GN, Esteva FJ. Novel pharmacological approaches in the treatment of breast cancer. Expert Opinion On Investigational Drugs. 12: 909-21. PMID 12783596 DOI: 10.1517/13543784.12.6.909 |
0.576 |
|
| 2003 |
Nahta R, Hortobagyi GN, Esteva FJ. Signal transduction inhibitors in the treatment of breast cancer. Current Medicinal Chemistry. Anti-Cancer Agents. 3: 201-16. PMID 12769778 DOI: 10.2174/1568011033482468 |
0.58 |
|
| 2003 |
Nahta R, Hortobágyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. The Oncologist. 8: 5-17. PMID 12604728 DOI: 10.1634/Theoncologist.8-1-5 |
0.579 |
|
| 2002 |
Nahta R, Iglehart JD, Kempkes B, Schmidt EV. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Research. 62: 2267-71. PMID 11956082 |
0.351 |
|
| 1999 |
Dong Q, Johnson SP, Colvin OM, Bullock N, Kilborn C, Runyon G, Sullivan DM, Easton J, Bigner DD, Nahta R, Marks J, Modrich P, Friedman HS. Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). Cancer Chemotherapy and Pharmacology. 43: 73-9. PMID 9923544 DOI: 10.1007/S002800050865 |
0.473 |
|
| Show low-probability matches. |